Myopic Choroidal Neovascularization
Last updated: February 6th, 2022
Summary of Evidence
Treatment of Myopic Choroidal Neovascularization
Intravitreal anti-VEGF injections
Ranibizumab
There was a significant improvement in BCVA and central macular thickness at 6 months in patients receiving intravitreal ranibizumab for myopic CNV.(REPAIR, 2013). {Tufail A, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, Cole M, Gale R, George S, Lotery AJ, Majid M, McKibbin M, Menon G, Yang Y, Andrews C, Brittain C, Osborne A. Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. Eye (Lond). 2013 Jun;27(6):709-15.}
Over 12 months, individualized ranibizumab treatment was effective in improving and sustaining BCVA in myopic CNV.(RADIANCE, 2013). {Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T, Wong TY, Silva R, Pilz S, Gekkieva M; RADIANCE Study Group. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014 Mar;121(3):682-92.e2.}
Aflibercept
Intravitreal aflibercept 2 mg was effective for treatment of myopic CNV, with a limited number of injections given within the first 8 weeks.(MYRROR, 2015). {Ikuno Y, Ohno-Matsui K, Wong TY, Korobelnik JF, Vitti R, Li T, Stemper B, Asmus F, Zeitz O, Ishibashi T; MYRROR Investigators. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study. Ophthalmology. 2015 Jun;122(6):1220-7.}
Responses